Table 1 Summary of characteristics and therapies of patients with ocular inflammatory diseases treated with intravenous cyclophosphamide
Case | Age (years), Sex | Total follow-up time (months) | Ocular disease | Underlying systemic disease | CP therapy duration | Side effects | Completion of therapy/flare-ups during or after therapy | Final therapy after CP | Previous IMTs |
|---|---|---|---|---|---|---|---|---|---|
1 | 89, Female | 32 | Necrotizing scleritis, Right eye | Rheumatoid arthritis | 11 | Leukopenia, abdominal pain | Yes/No | IFX (due to ongoing systemic disease activity) | MTX, ADA, IFX |
2 | 76, Female | 40 | Necrotizing scleritis, Right eye | IgG-4 sclerosing disease | 5 | None | Yes/No | MMF | MTX, RTX |
3 | 65, Male | 42 | Necrotizing scleritis, Both eyes | None | 28 | Leukopenia, fatigue, elevated liver enzymes | No/Yes (recurrence of scleral inflammation 6 months after CP stopped; restarted) | N/A | MMF, IFX |
4 | 70, Male | 45 | Orbital pseudotumor, Left eye | Dermatomyositis | 6 | Hematuria | Yes/No | MMF | MMF, IFX, Tacrolimus |
5 | 43, Male | 23 | HLA-B27 associated panuveitis and retinal vasculitis, Both eyes | Ankylosing spondylitis | 8 | Transient fever | No/No | N/A | AZA, MMF, MTX, ADA, IFX |
6 | 65, Female | 13 | Necrotizing scleritis, Left eye | None | 13 | Leukopenia | Yes/No | MTX | MTX |
7 | 50, Male | 42 | Peripheral ulcerative keratitis, Both eyes | None | 6 | Leukopenia | Yes/No | MMF | MTX |